D. Western Therapeutics Institute
4576
Needs Well
3992
Daiwa Cycle
5888
Osaka Yuka Industry
4124
Liberta
4935
(FY)Mar 31, 2024 | (FY)Mar 31, 2023 | |
---|---|---|
Total revenue | -2.06%10.12B | 10.33B |
Cost of revenue | -2.52%7.46B | 7.65B |
Gross profit | -0.76%2.66B | 2.68B |
Operating expense | 1.04%2.13B | 2.11B |
Operating profit | -7.38%529.56M | 571.77M |
Net non-operating interest income (expenses) | 35.82%-1.23M | -1.92M |
Non-operating interest income | --0 | --0 |
Non-operating interest expense | -35.82%1.23M | --1.92M |
Net investment income | -54.81%771K | 1.71M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | -7K |
Income from associates and other participating interests | ||
Special income (charges) | -112.92%-3.59M | 27.74M |
Less:Other special charges | 112.92%3.59M | ---27.74M |
Other non-operating income (expenses) | 22.71%44.54M | 36.3M |
Income before tax | -10.31%570.05M | 635.59M |
Income tax | -9.87%204.45M | 226.83M |
Net income | -10.56%365.61M | 408.76M |
Net income continuous operations | -10.56%365.61M | --408.76M |
Noncontrolling interests | ||
Net income attributable to the company | -10.56%365.61M | 408.76M |
Preferred stock dividends | ||
Other under preferred stock dividend | 0 | 0 |
Net income attributable to common stockholders | -10.56%365.61M | 408.76M |
Gross dividend payment | ||
Basic earnings per share | -10.56%60.9343 | 68.127 |
Diluted earnings per share | -10.56%60.9343 | 68.127 |
Dividend per share | ||
Currency Unit | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP |